查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018545

體外毒性測試市場：依服務類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

In-Vitro Toxicology Testing Market by Service Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，體外毒性測試市場價值將達到 147.8 億美元，到 2026 年將成長至 162.1 億美元，到 2032 年將達到 317.3 億美元，複合年成長率為 11.52%。

主要市場統計數據
基準年 2025 147.8億美元
預計年份：2026年 162.1億美元
預測年份 2032 317.3億美元
複合年成長率 (%) 11.52%

體外毒性測試作為實現更安全產品和加速轉化科學的關鍵支柱，其發展的基礎和戰略挑戰正在塑造體外毒性測試的演變。

體外毒性測試如今在產品安全、法規遵循和轉化科學的交會點上發揮著至關重要的作用。細胞生物學、微工程和計算毒理學的最新進展已將該領域的研究重點從主要驗證功能轉向早期研發階段的活性成分研究。隨著相關人員對預測效度和動物試驗倫理替代方案的需求日益成長，實驗室和服務供應商正在調整自身能力以滿足不斷變化的需求。因此，決策者必須在應對日益複雜的監管和商業環境的同時，平衡技術嚴謹性和營運擴充性。

技術快速融合、監管改革和相關人員的期望正在改變體外毒理學，並重新定義其檢驗和實施的途徑。

體外毒理學領域正經歷著一場變革，其驅動力包括技術融合、監管重新評估以及相關人員期望的轉變。高內涵成像、器官晶片平台和先進的3D培養技術，結合高通量自動化和機器學習，正在重塑毒理學風險的識別和情境化方式。同時，監管機構也越來越接受能夠證明其與人體相關性的替代方法，從而推動監管模式從單純的清單式合規轉向基於證據的預測性檢測檢驗。

評估 2025 年美國對體外毒理學工作流程和供應商徵收關稅的累積營運、供應鏈和合規性影響。

美國2025年實施的關稅政策對體外毒理學相關機構的營運和策略決策產生了累積影響。進口實驗室組件、客製化設備和某些耗材的關稅提高，加劇了依賴海外採購試劑和設備的實驗室的成本壓力。為此，各實驗室的採購團隊正在重新評估其供應商組合，盡可能優先考慮國內採購，並加快替代材料的檢驗，以維持檢測的性能和連續性。

整合服務類型、技術、應用和最終用戶趨勢的可操作細分洞察，有助於制定投資、合作和能力建立策略。

透過精細的細分觀點，我們可以揭示服務類型、技術方法、應用領域和最終用戶畫像如何塑造整個生態系統的策略重點和能力需求。所提供的服務包括生化分析、細胞培養分析（包括細胞株和原代細胞方法）以及計算模型，每種服務在通量、機制細節和轉化相關性方面都各具優勢。技術平台涵蓋了基於分析或成像的高通量篩檢、微流體技術、晶片器官系統和3D培養技術。平台選擇通常需要在規模和生理保真度之間進行權衡。

對美洲、歐洲、中東和非洲以及亞太地區進行區域比較分析：重點關注生態系統優勢、監管細微差別和合作途徑。

區域趨勢在塑造整個生態系統的能力、夥伴關係機會和監管環境方面發揮決定性作用。在美洲，製藥和生物技術研發中心的高度集中推動了對整合檢測方案和高通量解決方案的需求。同時，與進步監管機構的對話以及投資者的興趣正在加速創新平台的商業化。相較之下，歐洲、中東和非洲地區的監管環境和資金籌措環境則呈現多元化的特徵。儘管監管協調和基於倫理的政策努力正在為非動物調查方法創造有利環境，但仍需進行謹慎的策略調整，以應對各地區監管方面的細微差異。

體外毒理學領先服務供應商的競爭定位和創新概況：聚焦能力叢集、夥伴關係模式和差異化價值提案

競爭格局的核心在於少數幾家能夠成功整合卓越技術、可擴展服務模式和穩健資料管治的機構。領先的供應商憑藉涵蓋檢測方法開發、自動化、高內涵分析和計算毒理學的綜合能力脫穎而出，提供端到端解決方案，從而減少交接環節並加快決策速度。其他供應商則專注於器官模型系統和高通量成像等細分領域，透過在目標終點的調查方法和監管核准累積經驗，從而確立強大的市場地位。

為行業領導者提供優先且可操作的建議，以加快體外毒理學領域的應用，降低營運風險，並抓住轉化機會。

產業領導者應優先採取一系列行動，以加速技術應用、降低營運風險並實現轉換價值。首先，投資於模組化平台架構，實現試劑和組件的快速更換，從而最大限度地降低供應鏈風險，同時確保檢測的完整性。其次，正式建立資料互通性標準和主導評分卡的檢驗框架，以促進與監管機構和合作夥伴的協作。第三，與學術機構和創新公司建立策略夥伴關係，確保能夠取得早期方法，並共同開發商業性化規模的檢驗流程。

穩健的調查方法，結合了主要專家的意見、技術文獻的整合以及對檢測和技術性能指標的系統檢驗。

本分析的調查方法是基於三角測量法，整合了專家意見、有針對性的文獻綜述和系統性的技術檢驗。專家意見是透過對高級技術負責人、檢測方法開發人員和採購專家進行結構化訪談獲得的，旨在了解實際操作情況、檢驗流程和採購限制。補充性的二手研究包括對同行評審的方法學論文、監管指南和技術白皮書進行批判性評估，以闡明檢測方法的特性、平台功能和核准流程。

策略結論概述了致力於促進可靠和合乎倫理的體外毒性測試的相關人員的方向性優先事項、系統性促進因素和近期下一步措施。

總之，體外毒性測試正處於一個十字路口，科學創新與人們對符合倫理且與人體相關的安全性評估日益成長的期望在此交匯。從高通量篩檢和先進成像到微流體技術和晶片器官系統，各種互補技術的成熟正在產生更豐富的機制性見解，並為減少對體內模型的依賴創造了機會。同時，營運韌性、與監管機構的合作以及策略夥伴關係將決定哪些組織能夠將技術潛力轉化為永續的價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：體外毒性測試市場：依服務類型分類

  • 生化分析
  • 細胞培養實驗
    • 細胞株檢測
    • 原代細胞檢測
  • 計算模型

第9章：體外毒性測試市場：依技術分類

  • 高通量篩檢
    • 檢測基礎
    • 基於成像
  • 微流體技術
  • 器官晶片
  • 3D文化

第10章：體外毒性測試市場：依應用領域分類

  • 化妝品測試
    • 眼睛刺激
    • 皮膚刺激
  • 藥物發現
    • 先導藥物最適化
    • 目標檢驗
  • 安全評估
    • 致癌性
    • 細胞毒性
    • 基因毒性

第11章 體外毒性測試市場：依最終用戶分類

  • 學術研究機構
  • 受委託的研究機構
    • 大型合約研究組織
    • 小規模研究組織
  • 製藥和生物技術
    • 大型製藥企業
    • 中小型生技公司

第12章：體外毒性測試市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：體外毒性測試市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 體外毒性測試市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國體外毒性測試市場

第16章：中國體外毒性測試市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bio-Rad Laboratories, Inc.
  • BioIVT LLC
  • Catalent, Inc.
  • Emulate, Inc.
  • Eurofins Scientific SE
  • Evotec SE
  • Gentronix Limited
  • InSphero AG
  • Instem plc
  • Laboratory Corporation of America Holdings
  • Lonza Group Ltd.
  • Merck KGaA
  • Physiomics plc
  • Quest Diagnostics Incorporated
  • SGS SA
  • Stemina Biomarker Discovery, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
  • Xenometrix AG
Product Code: MRR-A339DAEFAF18

The In-Vitro Toxicology Testing Market was valued at USD 14.78 billion in 2025 and is projected to grow to USD 16.21 billion in 2026, with a CAGR of 11.52%, reaching USD 31.73 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.78 billion
Estimated Year [2026] USD 16.21 billion
Forecast Year [2032] USD 31.73 billion
CAGR (%) 11.52%

Foundations and strategic imperatives shaping the evolution of in-vitro toxicology testing as a critical pillar for safer products and accelerated translational science

In-vitro toxicology testing now occupies a pivotal role at the intersection of product safety, regulatory compliance, and translational science. Recent advances in cellular biology, microengineering, and computational toxicology have shifted the discipline from a largely confirmatory function to a proactive component of early-stage development. As stakeholders demand both higher predictive validity and ethical alternatives to animal testing, laboratories and service providers are repositioning capabilities to meet evolving expectations. Consequently, decision-makers must reconcile technical rigour with operational scalability while navigating an increasingly complex regulatory and commercial environment.

This introduction frames the executive summary by clarifying the key vectors that shape today's discipline: assay architecture, technology platforms, regulatory drivers, and end-user needs. It underscores why integration across biochemical assays, cell culture systems, and in silico approaches matters for translational success, and it establishes the premise that actionable intelligence must bridge scientific nuance with business realities. Throughout the report, stakeholders will find focused insights intended to support informed prioritization, partnership selection, and capability investment, all while preserving analytical integrity and accelerating time to insight.

Rapid technological convergence, regulatory recalibration, and stakeholder expectations driving transformational shifts in in-vitro toxicology that redefine validation and adoption pathways

The landscape of in-vitro toxicology is undergoing transformative shifts driven by technological convergence, regulatory recalibration, and changing stakeholder expectations. High-content imaging, organ-on-chip platforms, and advanced three-dimensional culture techniques are converging with high-throughput automation and machine learning to reshape how toxicological risk is identified and contextualized. Simultaneously, regulatory bodies are increasingly receptive to alternative methods that demonstrate human relevance, prompting a transition from check-box compliance to evidence-based validation of predictive assays.

These shifts are also altering commercial models: providers that combine assay development with scalable operational delivery and data analytics are emerging as preferred partners for pharmaceutical developers, cosmetic firms, and safety assessment organizations. Moreover, the maturation of microfluidics and organotypic systems is expanding the boundaries of mechanistic insight, enabling more nuanced evaluation of multi-organ interactions and chronic exposure effects. As a result, organizations that embrace cross-disciplinary integration-uniting cell biology, engineering, and computational toxicology-will be better positioned to translate methodological advancements into reproducible, regulatory-acceptable outcomes.

Assessment of the cumulative operational, supply chain, and compliance consequences stemming from United States tariffs in 2025 for in-vitro toxicology workflows and suppliers

The tariff environment introduced in the United States in 2025 has had a cumulative effect on the operational and strategic calculus of organizations engaged in in-vitro toxicology. Increased duties on imported laboratory components, bespoke instruments, and certain consumables have amplified cost pressures for laboratories that depend on internationally sourced reagents and devices. In response, procurement teams have re-evaluated supplier portfolios, prioritized domestic sourcing where feasible, and accelerated validation of alternative materials to preserve assay performance and continuity.

Beyond immediate cost implications, the tariff landscape has influenced supply chain architecture and investment timetables. Some providers have shifted inventory practices to buffer against volatility, while others have reconsidered near-term capital expenditures for equipment with long lead times. The combined effect has been a renewed emphasis on supply chain resilience, supplier diversification, and modular assay designs that reduce dependency on single-source components. Consequently, stakeholders are prioritizing partnerships with vendors that demonstrate transparent provenance, robust quality systems, and the ability to support rapid substitutions without compromising data integrity.

Actionable segmentation insights synthesizing service types, technologies, applications, and end-user dynamics to inform investment, collaboration, and capability development strategies

A nuanced segmentation lens reveals how service types, technology modalities, application areas, and end-user profiles shape strategic priorities and capability requirements across the ecosystem. Service offerings encompass biochemical assays, cell culture assays-including both cell line and primary cell approaches-and computational models, each delivering distinct strengths in throughput, mechanistic granularity, and translational relevance. Technology platforms range from high-throughput screening, which can be assay-based or imaging-based, to microfluidics, organ-on-chip systems, and three-dimensional culture techniques; the selection of platform often reflects a trade-off between scale and physiological fidelity.

Applications diversify strategic intent: cosmetics testing places premium emphasis on ocular and skin irritation assays that align with regulatory acceptability for non-animal methods, drug discovery leverages in-vitro systems for lead optimization and target validation where speed and mechanistic insight accelerate candidate progression, and safety assessment requires focused evaluations of carcinogenicity, cytotoxicity, and genotoxicity that prioritize reproducibility and regulatory traceability. End users further modulate priorities, with academic and research institutes driving methodological innovation, contract research organizations balancing throughput with service flexibility across large-scale and smaller CRO models, and pharmaceutical and biotech firms-both large pharma and small-to-medium biotech-demanding integrated solutions that can be embedded into drug development pipelines. Collectively, these segmentation vectors point to an ecosystem where interoperability, standardized data frameworks, and validated substitution pathways unlock the greatest commercial and scientific value.

Comparative regional intelligence across the Americas, Europe, Middle East & Africa, and Asia-Pacific highlighting ecosystem strengths, regulatory nuances, and collaboration vectors

Regional dynamics play a determinative role in shaping capabilities, partnership opportunities, and regulatory trajectories across the ecosystem. In the Americas, a dense concentration of pharmaceutical and biotech R&D centers drives demand for integrated assay packages and high-throughput solutions, while progressive regulatory dialogues and investor interest support rapid commercialization of innovative platforms. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory frameworks and funding landscapes, where harmonization efforts and ethically driven policies create fertile ground for non-animal methodologies, but where localized regulatory nuances demand careful strategy alignment.

Asia-Pacific is characterized by rapid capacity expansion, significant public and private investment in life sciences infrastructure, and a growing base of skilled technical personnel; as a result, this region is increasingly competitive for both service delivery and technological innovation. Across all regions, cross-border collaborations and regional centers of excellence are emerging as practical mechanisms to accelerate method validation and harmonize data standards. Therefore, stakeholders should prioritize region-specific engagement strategies that account for regulatory posture, talent availability, and logistics, while leveraging cross-regional partnerships to distribute risk and codify best practices.

Competitive positioning and innovation profiling of leading service providers emphasizing capability clusters, partnership models, and differentiated value propositions in in-vitro toxicology

Competitive dynamics center on a subset of organizations that have successfully combined technical excellence with scalable service models and credible data governance. Leading providers differentiate through integrated capabilities that span assay development, automation, high-content analytics, and computational toxicology, enabling them to offer end-to-end solutions that reduce handoffs and accelerate decision timelines. Others specialize in niche domains such as organotypic systems or high-throughput imaging, carving defensible positions by achieving methodological depth and regulatory recognition in targeted endpoints.

Strategic partnerships, licensing of proprietary assay chemistries, and collaborations with academic centers are common mechanisms for maintaining technological edge. Moreover, companies that invest in rigorous quality systems and transparent data pipelines gain traction with risk-averse end users who require auditable evidence for regulatory interactions. For potential partners and acquirers, value often attaches to unique assay libraries, validated organ-on-chip platforms, and demonstrated proficiency in bridging mechanistic insights with actionable safety endpoints. Consequently, competitive differentiation increasingly relies on a hybrid of scientific credibility, operational reliability, and the ability to translate complex data into concise, regulator-ready narratives.

Prioritized and pragmatic recommendations for industry leaders to accelerate adoption, de-risk operations, and capitalize on translational opportunities in in-vitro toxicology

Industry leaders should pursue a set of prioritized actions to accelerate adoption, de-risk operations, and capture translational value. First, invest in modular platform architectures that allow rapid substitution of reagents and components to minimize supply chain vulnerability while preserving assay integrity. Second, formalize data interoperability standards and scorecard-driven validation frameworks to facilitate regulatory engagement and cross-partner collaboration. Third, cultivate strategic partnerships with academic centers and technology innovators to access early-stage methods and co-develop validation pathways that can be scaled commercially.

In parallel, organizations should build multidisciplinary teams that fuse cell biology, engineering, and computational expertise to reduce siloed decision-making and enable end-to-end methodological ownership. Risk management must include proactive inventory strategies and supplier diversification, while commercialization efforts should emphasize transparent performance metrics and case studies that demonstrate translational relevance. Finally, leadership must prioritize customer-centric service design-offering configurable packages that align with varied end-user needs from high-throughput screening for lead discovery to physiologically faithful organotypic assays for safety assessment.

Robust research methodology detailing triangulation of primary expert inputs, technical literature synthesis, and systematic validation of assay and technology performance metrics

The research methodology underpinning this analysis relies on a triangulated approach that synthesizes primary expert input, targeted literature review, and systematic technical validation. Primary inputs were obtained through structured interviews with senior technical leaders, assay developers, and procurement specialists to capture operational realities, validation practices, and procurement constraints. Complementary secondary analysis entailed a critical appraisal of peer-reviewed method papers, regulatory guidance, and technical white papers to contextualize assay characteristics, platform capabilities, and acceptance pathways.

To ensure robustness, findings were cross-validated through comparative case analyses of representative assay deployments and technology adoption scenarios, focusing on reproducibility, transferability, and regulatory alignment. Attention was paid to methodological transparency, including documentation of assay endpoints, control strategies, and data management practices. Where possible, the methodology emphasized practical applicability, aiming to produce insights that stakeholders can use to inform capability development, partnership selection, and risk mitigation without relying on speculative projections.

Strategic conclusion summarizing directional priorities, systemic enablers, and immediate next steps for stakeholders committed to advancing reliable and ethical in-vitro toxicology testing

In conclusion, in-vitro toxicology testing stands at an inflection point where scientific innovation converges with heightened expectations for ethical, human-relevant safety assessment. The maturation of complementary technologies-from high-throughput screening and advanced imaging to microfluidics and organ-on-chip systems-creates opportunities to generate richer mechanistic insights and to reduce reliance on in vivo models. At the same time, operational resilience, regulatory engagement, and strategic partnerships will determine which organizations translate technological promise into sustained value.

Stakeholders who adopt interoperable data standards, prioritize modular assay design, and actively engage with regulatory stakeholders will be best positioned to advance reliable and ethically defensible practices. Immediate next steps include strengthening supplier networks, validating substitution strategies for critical components, and investing in cross-disciplinary talent. By aligning technical priorities with pragmatic operational planning, organizations can accelerate the adoption of predictive, reproducible, and scalable in-vitro toxicology approaches that serve both public health and commercial objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Vitro Toxicology Testing Market, by Service Type

  • 8.1. Biochemical Assays
  • 8.2. Cell Culture Assays
    • 8.2.1. Cell Line Assays
    • 8.2.2. Primary Cell Assays
  • 8.3. Computational Models

9. In-Vitro Toxicology Testing Market, by Technology

  • 9.1. High Throughput Screening
    • 9.1.1. Assay Based
    • 9.1.2. Imaging Based
  • 9.2. Microfluidics
  • 9.3. Organ On Chip
  • 9.4. Three Dimensional Culture

10. In-Vitro Toxicology Testing Market, by Application

  • 10.1. Cosmetics Testing
    • 10.1.1. Ocular Irritation
    • 10.1.2. Skin Irritation
  • 10.2. Drug Discovery
    • 10.2.1. Lead Optimization
    • 10.2.2. Target Validation
  • 10.3. Safety Assessment
    • 10.3.1. Carcinogenicity
    • 10.3.2. Cytotoxicity
    • 10.3.3. Genotoxicity

11. In-Vitro Toxicology Testing Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Contract Research Organizations
    • 11.2.1. Large Scale CROs
    • 11.2.2. Small Scale CROs
  • 11.3. Pharma And Biotech
    • 11.3.1. Large Pharma
    • 11.3.2. Small And Medium Biotech

12. In-Vitro Toxicology Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. In-Vitro Toxicology Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. In-Vitro Toxicology Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States In-Vitro Toxicology Testing Market

16. China In-Vitro Toxicology Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bio-Rad Laboratories, Inc.
  • 17.6. BioIVT LLC
  • 17.7. Catalent, Inc.
  • 17.8. Emulate, Inc.
  • 17.9. Eurofins Scientific SE
  • 17.10. Evotec SE
  • 17.11. Gentronix Limited
  • 17.12. InSphero AG
  • 17.13. Instem plc
  • 17.14. Laboratory Corporation of America Holdings
  • 17.15. Lonza Group Ltd.
  • 17.16. Merck KGaA
  • 17.17. Physiomics plc
  • 17.18. Quest Diagnostics Incorporated
  • 17.19. SGS S.A.
  • 17.20. Stemina Biomarker Discovery, Inc.
  • 17.21. Thermo Fisher Scientific Inc.
  • 17.22. WuXi AppTec Co., Ltd.
  • 17.23. Xenometrix AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL LINE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL LINE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL LINE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PRIMARY CELL ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PRIMARY CELL ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PRIMARY CELL ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COMPUTATIONAL MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COMPUTATIONAL MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COMPUTATIONAL MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY ASSAY BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY ASSAY BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY ASSAY BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY IMAGING BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY IMAGING BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY IMAGING BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY ORGAN ON CHIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY ORGAN ON CHIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY ORGAN ON CHIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY THREE DIMENSIONAL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY THREE DIMENSIONAL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY THREE DIMENSIONAL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY OCULAR IRRITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY OCULAR IRRITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY OCULAR IRRITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SKIN IRRITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SKIN IRRITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SKIN IRRITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CARCINOGENICITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CARCINOGENICITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CARCINOGENICITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CYTOTOXICITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CYTOTOXICITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CYTOTOXICITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GENOTOXICITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GENOTOXICITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GENOTOXICITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY LARGE SCALE CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY LARGE SCALE CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY LARGE SCALE CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SMALL SCALE CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SMALL SCALE CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SMALL SCALE CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SMALL AND MEDIUM BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SMALL AND MEDIUM BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SMALL AND MEDIUM BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 207. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 212. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 214. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 216. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 243. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 248. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 250. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 251. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 252. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 254. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 255. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 260. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 262. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 263. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 264. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, 2018-2032 (USD MILLION)